Replimune Group, Inc. (NASDAQ:REPL) Stock Position Raised by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 24.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 184,208 shares of the company’s stock after buying an additional 36,689 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Replimune Group were worth $2,019,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in REPL. Nisa Investment Advisors LLC raised its holdings in Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares in the last quarter. Point72 DIFC Ltd acquired a new position in shares of Replimune Group during the second quarter valued at about $57,000. Arizona State Retirement System bought a new position in Replimune Group during the second quarter valued at about $108,000. Quest Partners LLC increased its position in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after purchasing an additional 3,150 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Replimune Group by 82.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock valued at $144,000 after buying an additional 5,926 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Replimune Group

In other news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 8.80% of the stock is owned by company insiders.

Replimune Group Stock Down 3.4 %

NASDAQ:REPL opened at $12.64 on Tuesday. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock has a 50-day simple moving average of $12.14 and a 200 day simple moving average of $10.32. The company has a market cap of $864.83 million, a PE ratio of -4.14 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, sell-side analysts expect that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. BMO Capital Markets lifted their target price on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a report on Friday, November 22nd. Roth Mkm assumed coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. Finally, Jefferies Financial Group upped their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $17.29.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.